Glaukos (NYSE:GKOS) Price Target Raised to $202.00

Glaukos (NYSE:GKOS) had its price objective upped by BTIG Research from $193.00 to $202.00 in a research note released on Thursday, MarketBeat Ratings reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Other analysts have also recently issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price target (up from $165.00) on shares of Glaukos in a research note on Thursday, July 30th. HC Wainwright raised their price objective on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Needham & Company LLC boosted their target price on Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Citigroup boosted their target price on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $178.08.

Glaukos Trading Up 0.4%

Glaukos stock opened at $185.66 on Thursday. The stock has a market cap of $10.95 billion, a P/E ratio of -57.13 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. Glaukos has a 1 year low of $73.16 and a 1 year high of $191.62. The firm’s 50 day moving average price is $157.38 and its 200-day moving average price is $131.62.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. Glaukos’s revenue for the quarter was up 49.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) earnings per share. On average, equities analysts predict that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 60,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the sale, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 113,025 shares of company stock worth $19,600,006 in the last ninety days. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Glaukos in the 2nd quarter valued at approximately $1,333,318,000. Janus Henderson Group PLC increased its position in shares of Glaukos by 77.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Glaukos during the 2nd quarter valued at $679,614,000. Wellington Management Group LLP raised its holdings in Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after buying an additional 336,266 shares during the period. Finally, Primecap Management Co. CA lifted its position in Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after buying an additional 1,123,140 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.